Digirad (NASDAQ: DRAD) is one of 79 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare Digirad to related businesses based on the strength of its earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.
Valuation and Earnings
This table compares Digirad and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Digirad||$125.47 million||$14.30 million||-3.83|
|Digirad Competitors||$2.14 billion||$234.27 million||-86.75|
Risk & Volatility
Digirad has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, Digirad’s rivals have a beta of 1.20, suggesting that their average share price is 20% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Digirad and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Digirad currently has a consensus price target of $6.00, indicating a potential upside of 170.27%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 0.37%. Given Digirad’s stronger consensus rating and higher probable upside, research analysts plainly believe Digirad is more favorable than its rivals.
This table compares Digirad and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
53.1% of Digirad shares are held by institutional investors. Comparatively, 51.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 11.9% of Digirad shares are held by insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Digirad pays an annual dividend of $0.22 per share and has a dividend yield of 9.9%. Digirad pays out -37.9% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 28.4% of their earnings in the form of a dividend. Digirad is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
Digirad beats its rivals on 11 of the 15 factors compared.
Digirad Corporation provides healthcare solutions. The Company’s segments include Diagnostic Services, Mobile Healthcare, Diagnostic Imaging and Medical Device Sales and Services. Through Diagnostic Services, the Company offers an imaging services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center. Through Mobile Healthcare segment, the Company provides contract sales services and diagnostic imaging services. Through Diagnostic Imaging segment, the Company sells its internally developed solid-state gamma camera imaging systems and camera maintenance contracts. Through Medical Device Sales and Services segment, the Company provides contract sales services, as well as warranty and post-warranty services, under contract with Philips Healthcare within a defined region in the upper Midwest region of the United States.
Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.